Revvity, Inc. (NYSE:RVTY – Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 3,600,000 shares, an increase of 33.8% from the March 31st total of 2,690,000 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average trading volume of 888,500 shares, the short-interest ratio is currently 4.1 days.
Insider Buying and Selling
In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the completion of the transaction, the insider now owns 92,801 shares in the company, valued at $9,677,288.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.60% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of RVTY. Vanguard Group Inc. acquired a new position in Revvity in the third quarter valued at $1,579,487,000. Capital Research Global Investors purchased a new stake in shares of Revvity in the fourth quarter valued at about $838,080,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Revvity in the fourth quarter valued at about $188,368,000. Norges Bank purchased a new stake in shares of Revvity in the fourth quarter valued at about $129,483,000. Finally, Northern Trust Corp purchased a new stake in shares of Revvity in the fourth quarter valued at about $127,401,000. 86.65% of the stock is currently owned by institutional investors and hedge funds.
Revvity Stock Down 2.4 %
Revvity (NYSE:RVTY – Get Free Report) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.94 by $0.04. The firm had revenue of $649.90 million for the quarter, compared to analyst estimates of $646.83 million. Revvity had a net margin of 25.20% and a return on equity of 7.41%. Revvity’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period last year, the business earned $1.01 EPS. As a group, equities analysts anticipate that Revvity will post 4.65 earnings per share for the current fiscal year.
Revvity Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a $0.07 dividend. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. Revvity’s dividend payout ratio is presently 5.09%.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on RVTY shares. Stifel Nicolaus upped their price target on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Raymond James upped their price target on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. TD Cowen upped their price target on shares of Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $88.00 to $125.00 in a research note on Thursday, January 4th. Finally, KeyCorp upped their price target on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Revvity currently has an average rating of “Moderate Buy” and a consensus price target of $118.17.
View Our Latest Research Report on Revvity
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Read More
- Five stocks we like better than Revvity
- How to Use the MarketBeat Dividend Calculator
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Energy and Oil Stocks Explained
- Hilton Demonstrates Asset Light is Right for Investors
- 3 Small Caps With Big Return Potential
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.